Medicine
Comparative Effectiveness of Immunotherapy Versus Chemotherapy in Non-Small Cell Lung Cancer
Quick fact
In clinical trials, immunotherapy (such as pembrolizumab) has shown a 5-year survival rate of about 31.9% for previously untreated advanced non-small cell lung cancer with high PD-L1 expression, compared to 16.3% with chemotherapy.
Why this is interesting
What if the body's own immune system could be trained to fight cancer more effectively than chemotherapy? In non-small cell lung cancer, that is now a reality—but it doesn't work for everyone.